Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

Abstract Early reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast canc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tianli Hui, Chao Shang, Liu Yang, Meiqi Wang, Ruoyang Li, Zhenchuan Song
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9acc9659bf2f495683f2261e7cfaff34
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9acc9659bf2f495683f2261e7cfaff34
record_format	dspace
spelling	oai:doaj.org-article:9acc9659bf2f495683f2261e7cfaff342021-12-02T15:36:13ZMetformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus10.1038/s41598-021-89475-y2045-2322https://doaj.org/article/9acc9659bf2f495683f2261e7cfaff342021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89475-yhttps://doaj.org/toc/2045-2322Abstract Early reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast cancer patients with T2DM. A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled. According to the medication treatment, all the patients were divided as non-diabetes group, metformin group and insulin group. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3553 patients (median follow up of 85 months) and estimated with the Kaplan–Meier method followed by a log-rank test. Multivariate Cox proportional hazards regression model was applied. The results showed that there was a significant survival difference among non-diabetes group, metformin group and insulin group, 5-year DFS was 85.8%, 96.1%, 73.0%, and 5-year OS was 87.3%, 97.1%, 73.3% respectively (P < 0.05). Prognostic analysis showed metformin was significantly associated with better DFS and OS. Our results suggested that metformin may have a good effect on the survival of invasive breast cancer patients with T2DM.Tianli HuiChao ShangLiu YangMeiqi WangRuoyang LiZhenchuan SongNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tianli Hui Chao Shang Liu Yang Meiqi Wang Ruoyang Li Zhenchuan Song Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus
description	Abstract Early reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast cancer patients with T2DM. A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled. According to the medication treatment, all the patients were divided as non-diabetes group, metformin group and insulin group. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3553 patients (median follow up of 85 months) and estimated with the Kaplan–Meier method followed by a log-rank test. Multivariate Cox proportional hazards regression model was applied. The results showed that there was a significant survival difference among non-diabetes group, metformin group and insulin group, 5-year DFS was 85.8%, 96.1%, 73.0%, and 5-year OS was 87.3%, 97.1%, 73.3% respectively (P < 0.05). Prognostic analysis showed metformin was significantly associated with better DFS and OS. Our results suggested that metformin may have a good effect on the survival of invasive breast cancer patients with T2DM.
format	article
author	Tianli Hui Chao Shang Liu Yang Meiqi Wang Ruoyang Li Zhenchuan Song
author_facet	Tianli Hui Chao Shang Liu Yang Meiqi Wang Ruoyang Li Zhenchuan Song
author_sort	Tianli Hui
title	Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus
title_short	Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus
title_full	Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus
title_fullStr	Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus
title_full_unstemmed	Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus
title_sort	metformin improves the outcomes in chinese invasive breast cancer patients with type 2 diabetes mellitus
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9acc9659bf2f495683f2261e7cfaff34
work_keys_str_mv	AT tianlihui metforminimprovestheoutcomesinchineseinvasivebreastcancerpatientswithtype2diabetesmellitus AT chaoshang metforminimprovestheoutcomesinchineseinvasivebreastcancerpatientswithtype2diabetesmellitus AT liuyang metforminimprovestheoutcomesinchineseinvasivebreastcancerpatientswithtype2diabetesmellitus AT meiqiwang metforminimprovestheoutcomesinchineseinvasivebreastcancerpatientswithtype2diabetesmellitus AT ruoyangli metforminimprovestheoutcomesinchineseinvasivebreastcancerpatientswithtype2diabetesmellitus AT zhenchuansong metforminimprovestheoutcomesinchineseinvasivebreastcancerpatientswithtype2diabetesmellitus
_version_	1718386369863090176

Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

Ejemplares similares